Multiepitope Fusion(多表位融合)研究综述
Multiepitope Fusion 多表位融合 - To overcome these challenges, we applied a toxoid fusion strategy and a novel epitope- and structure-based multiepitope fusion antigen (MEFA) vaccinology platform to construct two chimeric multivalent proteins, toxoid fusion 3xSTaN12S-mnLTR192G/L211A and adhesin CFA/I/II/IV MEFA, and demonstrated that the proteins induced protective antibodies against STa and heat-labile toxin (LT) produced by all ETEC strains or the seven most important ETEC adhesins (CFA/I and CS1 to CS6) expressed by the ETEC strains causing 60 to 70% of diarrheal cases and moderate to severe cases. [1] The selected highly immunogenic T-cell epitopes were then used to design two multiepitope fusion constructs. [2] Multiepitope fusion protein based nano-p-ELISA displayed significantly sensitivity and specificity compared to Brucella LPS antigen. [3] For the design of a therapeutic vaccine candidate, we utilized immunoinformatics tools to design a potential multiepitope fusion construct based on L1 and E7 genes from different high- and low-risk HPV types. [4] The verified epitopes were connected in series to construct a multiepitope fusion protein, goat, bovine brucellosis sera, and rabbit sera were collected to verify the antigenicity and specificity of this protein. [5] In this study, we subcutaneously (SC) immunized mice with the ETEC adhesin-based vaccine, CFA/I/II/IV MEFA (multiepitope fusion antigen), adjuvanted with dmLT and examined the impact of dmLT on antibody responses specific to the seven adhesins in the vaccine construction [CFA/I, CFA/II (CS1, CS2, CS3) and CFA/IV (CS4, CS5, CS6)]. [6] While conventional vaccinology approaches encounter difficulties at integrating or including heterogeneous ETEC fimbria and toxin antigens into a vaccine product, multiepitope fusion antigen (MEFA) structural vaccinology provides a new platform to combine neutralizing antigenic elements or epitopes from various heterogeneous virulence factors for broad immunity and protection. [7]为了克服这些挑战，我们应用类毒素融合策略和基于表位和结构的新型多表位融合抗原 (MEFA) 疫苗学平台来构建两种嵌合多价蛋白，类毒素融合 3xSTaN12S-mnLTR192G/L211A 和粘附素 CFA/I/II/ IV MEFA，并证明这些蛋白质诱导了针对所有 ETEC 菌株或 ETEC 菌株表达的七种最重要的 ETEC 粘附素（CFA/I 和 CS1 至 CS6）产生的 STa 和热不稳定毒素 (LT) 的保护性抗体，导致 60 70%的腹泻病例和中度至重度病例。 [1] 然后使用选择的高免疫原性 T 细胞表位来设计两个多表位融合构建体。 [2] 与布鲁氏菌 LPS 抗原相比，基于多表位融合蛋白的 nano-p-ELISA 显示出显着的敏感性和特异性。 [3] 为了设计治疗性疫苗候选者，我们利用免疫信息学工具设计了一种潜在的多表位融合构建体，该构建体基于来自不同高危和低危 HPV 类型的 L1 和 E7 基因。 [4] 将验证过的表位串联构建多表位融合蛋白，采集山羊、牛布鲁氏菌病血清、兔血清，验证该蛋白的抗原性和特异性。 [5] 在这项研究中，我们用基于 ETEC 粘附素的疫苗 CFA/I/II/IV MEFA（多表位融合抗原）对小鼠进行皮下 (SC) 免疫，辅以 dmlT，并检查 dmlT 对七种粘附素特异性抗体反应的影响在疫苗构建中[CFA/I、CFA/II（CS1、CS2、CS3）和CFA/IV（CS4、CS5、CS6）]。 [6] 虽然传统的疫苗学方法在将异质 ETEC 菌毛和毒素抗原整合或包含到疫苗产品中遇到困难，但多表位融合抗原 (MEFA) 结构疫苗学提供了一个新平台，可以结合来自各种异质毒力因子的中和抗原元件或表位，以实现广泛的免疫和保护. [7]
multiepitope fusion antigen
To overcome these challenges, we applied a toxoid fusion strategy and a novel epitope- and structure-based multiepitope fusion antigen (MEFA) vaccinology platform to construct two chimeric multivalent proteins, toxoid fusion 3xSTaN12S-mnLTR192G/L211A and adhesin CFA/I/II/IV MEFA, and demonstrated that the proteins induced protective antibodies against STa and heat-labile toxin (LT) produced by all ETEC strains or the seven most important ETEC adhesins (CFA/I and CS1 to CS6) expressed by the ETEC strains causing 60 to 70% of diarrheal cases and moderate to severe cases. [1] In this study, we subcutaneously (SC) immunized mice with the ETEC adhesin-based vaccine, CFA/I/II/IV MEFA (multiepitope fusion antigen), adjuvanted with dmLT and examined the impact of dmLT on antibody responses specific to the seven adhesins in the vaccine construction [CFA/I, CFA/II (CS1, CS2, CS3) and CFA/IV (CS4, CS5, CS6)]. [2] While conventional vaccinology approaches encounter difficulties at integrating or including heterogeneous ETEC fimbria and toxin antigens into a vaccine product, multiepitope fusion antigen (MEFA) structural vaccinology provides a new platform to combine neutralizing antigenic elements or epitopes from various heterogeneous virulence factors for broad immunity and protection. [3]为了克服这些挑战，我们应用类毒素融合策略和基于表位和结构的新型多表位融合抗原 (MEFA) 疫苗学平台来构建两种嵌合多价蛋白，类毒素融合 3xSTaN12S-mnLTR192G/L211A 和粘附素 CFA/I/II/ IV MEFA，并证明这些蛋白质诱导了针对所有 ETEC 菌株或 ETEC 菌株表达的七种最重要的 ETEC 粘附素（CFA/I 和 CS1 至 CS6）产生的 STa 和热不稳定毒素 (LT) 的保护性抗体，导致 60 70%的腹泻病例和中度至重度病例。 [1] 在这项研究中，我们用基于 ETEC 粘附素的疫苗 CFA/I/II/IV MEFA（多表位融合抗原）对小鼠进行皮下 (SC) 免疫，辅以 dmlT，并检查 dmlT 对七种粘附素特异性抗体反应的影响在疫苗构建中[CFA/I、CFA/II（CS1、CS2、CS3）和CFA/IV（CS4、CS5、CS6）]。 [2] 虽然传统的疫苗学方法在将异质 ETEC 菌毛和毒素抗原整合或包含到疫苗产品中遇到困难，但多表位融合抗原 (MEFA) 结构疫苗学提供了一个新平台，可以结合来自各种异质毒力因子的中和抗原元件或表位，以实现广泛的免疫和保护. [3]
multiepitope fusion construct 多表位融合构建体
The selected highly immunogenic T-cell epitopes were then used to design two multiepitope fusion constructs. [1] For the design of a therapeutic vaccine candidate, we utilized immunoinformatics tools to design a potential multiepitope fusion construct based on L1 and E7 genes from different high- and low-risk HPV types. [2]然后使用选择的高免疫原性 T 细胞表位来设计两个多表位融合构建体。 [1] 为了设计治疗性疫苗候选者，我们利用免疫信息学工具设计了一种潜在的多表位融合构建体，该构建体基于来自不同高危和低危 HPV 类型的 L1 和 E7 基因。 [2]
multiepitope fusion protein 多表位融合蛋白
Multiepitope fusion protein based nano-p-ELISA displayed significantly sensitivity and specificity compared to Brucella LPS antigen. [1] The verified epitopes were connected in series to construct a multiepitope fusion protein, goat, bovine brucellosis sera, and rabbit sera were collected to verify the antigenicity and specificity of this protein. [2]与布鲁氏菌 LPS 抗原相比，基于多表位融合蛋白的 nano-p-ELISA 显示出显着的敏感性和特异性。 [1] 将验证过的表位串联构建多表位融合蛋白，采集山羊、牛布鲁氏菌病血清、兔血清，验证该蛋白的抗原性和特异性。 [2]